Target intelligence / Profile preview

Small hydrophobic protein ectodomain of Respiratory Syncytial Virus subgroup A (SHe)

Target
SHe
Molecular classification
Viroporin, Viral surface protein, Ion channel
01

Overview

The Small Hydrophobic (SH) protein of Respiratory Syncytial Virus (RSV) subgroup A is a 64-65 amino acid type II transmembrane protein that functions as a viroporin, forming pentameric ion channels in host cell membranes (Gan et al., 2012, Protein & Cell). While the SH protein is not essential for viral replication in vitro, it plays a critical role in vivo by modulating host immune responses, such as inhibiting Tumor Necrosis Factor-alpha (TNF-alpha) signaling to prevent early apoptosis of infected cells (Fuentes et al., 2007, Journal of Virology). The extracellular C-terminal domain, known as SHe, consists of approximately 23 amino acids and is highly conserved within RSV subgroup A (Schepens et al., 2014, Nature Communications). SHe has become a significant therapeutic target because it is expressed on the surface of infected cells but is relatively shielded from the immune system during natural infection. Experimental vaccines targeting SHe do not induce neutralizing antibodies but instead trigger antibody-dependent cellular cytotoxicity (ADCC), leading to the clearance of infected cells and reduced viral load (Schepens et al., 2011, EMBO Molecular Medicine). This target is particularly relevant for developing broad-spectrum RSV prophylaxis to prevent severe lower respiratory tract infections like bronchiolitis and pneumonia.

Other names
RSV SHeSmall hydrophobic protein ectodomainSH proteinRSV-A SH protein
02

Mechanism of action

Induction of antibody-dependent cellular cytotoxicity (ADCC) against RSV-infected cells and potential inhibition of viroporin-mediated ion channel function (Schepens et al., 2011, EMBO Molecular Medicine).

03

Biological functions

Ion channel activityInhibition of TNF-alpha signalingModulation of apoptosisViral assembly
04

Disease associations

Infection
05

Safety considerations

Potential for vaccine-enhanced respiratory disease (ERD)Subgroup-specific protection
06

Interacting drugs

SHe-KLH (experimental vaccine)

1 more in the full profile.

07

Biomarkers

Anti-SHe IgG titers

Beyond the preview

Go deeper on Small hydrophobic protein ectodomain of Respiratory Syncytial Virus subgroup A (SHe).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small hydrophobic protein ectodomain of Respiratory Syncytial Virus subgroup A (SHe).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call